

The board of directors' of Swedish Orphan Biovitrum AB (publ) statement in accordance with Chapter 19, Sections 22-23 of the Swedish Companies Act

In view of the board of directors' proposal on an authorization for the board of directors to resolve on a directed offer to acquire all of the company's issued series C shares, the board of directors hereby makes the following statement in accordance with Chapter 19 Section 22 of the Swedish Companies Act.

The board of directors is convinced that the implementation of the company's share programs 2008-2011 and the proposed performance based long-term share program for the CEO (jointly referred to as the "Share Programs") will be beneficial to both the company and its shareholders. Repurchase of the series C shares constitutes a step in the implementation of the Share Programs, for the purpose of creating share delivery capacity for the company, as well as to secure future cash flow effects of payments of social security costs, under these programs. The intention is that the repurchased series C shares shall be converted into common shares in such number that is required to fulfill the share delivery commitments and to secure the cash flow effects under the Share Programs. The converted common shares will thereafter be transferred free of charge (i) to the employees participating in the Share Programs and (ii) in the market in order to cover payments of social security costs connected with the Share Programs.

The board of directors is of the opinion, in view of the above, that the proposed repurchases are justifiable with respect to the amount of equity required by the nature, scope and risks associated with the operations of the company and the group, as well as the company's and the group's consolidation requirements, liquidity and overall financial position. The board of directors has also considered other known circumstances that were not part of the aforementioned assessments, and in doing so has found nothing to suggest that the proposed value transfers are not justifiable.

Pursuant to Chapter 19, Section 23 of the Swedish Companies Act, the board of directors further specifies that the annual general meeting 2011 resolved that no dividends were to be distributed to the shareholders and that the retained disposable profits consequently amount to SEK 3,458,079,130.

Stockholm, 29 June 2011
Swedish Orphan Biovitrum AB (publ)
the Board of Directors